A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
← catalyst calendarNCT06131840 · readout in 1,120 d
Sponsored by Seagen, a wholly owned subsidiary of Pfizer (industry) · PFE — their whole pipeline →. With Sanofi.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
914estimated
Sites
48
Countries
Canada, China, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-20 | actual | When the study began enrolling |
| Primary completion | 2029-09-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-09-12 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Colorectal Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Stomach Neoplasms
- Pancreatic Ductal Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Small Cell Lung Carcinoma
Interventions
- Drug: PF-08046050 — also filed as SAR445953; SGN-CEACAM5C
- Drug: bevacizumab
- Drug: 5-Fluorouracil (5-FU)
- Drug: Oxaliplatin
- Drug: Leucovorin (LV)
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Through 30-37 days after the last study treatment, up to approximately 2 years
Number of participants with laboratory abnormalities
measured Through 30-37 days after the last study treatment, up to approximately 2 years
Number of dose modifications due to AEs
measured Through end of treatment up to approximately 2 years
Number of participants with dose-limiting toxicities (DLTs)
measured Up to 28 days
Number of participants with DLTs by dose level
measured Up to 28 days
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed